HOME > Business Wire > Article
European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics
The Friendly CDMO Expert’s Milan Cell and Gene Center of Excellence Achieves 10th Major Regulatory Product Approval
MILAN--( BUSINESS WIRE )-- Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel – obe-cel), AGC Biologics’ Milan site achieved its 10th product approval from the European Medicines Agency or the U.S. Food and Drug Administration.
Developed by Autolus Therapeutics, AUCATZYL® is now approved to treat adult patients (age 26 and older) in 27 European Union member states with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This follows the therapy’s prior authorizations from the FDA in November 2024 and the U.K. Medicines and Healthcare products Regulatory Agency in April 2025.
This latest step further solidifies AGC Biologics’ Milan Cell and Gene Center of Excellence’s reputation as a global leader in the field, built on a 30-year track record of quality, reliability, and regulatory success.
“This European approval for Autolus is a milestone we are thrilled to be part of. Our goal is to be the industry’s safe harbor: a trusted, friendly expert CDMO that de-risks the complex path to commercialization,” said Alberto Santagostino, CEO and President, AGC Biologics. “By ensuring a reliable supply of their vital lentiviral vector, we empower our partners to focus on patients. Congratulations to the entire Autolus team.”
The partnership between Autolus and AGC Biologics Milan began in 2020, with the CDMO tasked to develop, manufacture, and supply the viral vectors for Autolus’ obe-cel CAR-T product candidate.
“From the start of our partnership in 2020, through the FDA approval and now this European authorization, our collaboration with Autolus has been a model of true partnership,” said Luca Alberici, General Manager, AGC Biologics Milan. “The team’s sustained dedication and technical excellence is a direct result of our ability to work seamlessly with the Autolus team to meet the demands of commercial-scale manufacturing for a global market.”
With its 30-year track record and 10 product approvals by the EMA and FDA, the AGC Biologics Milan site is a global leader with deep expertise in complex cell and gene therapy projects. The team has guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory guidelines, quality performance metrics, and the unique complexities of technology transfers and manufacturing scale-up.
To learn more about AGC Biologics’ global cell therapy services, visit www.agcbio.com/capabilities/cell-therapy , and for more on the CDMO’s viral vector offerings, visit www.agcbio.com/capabilities/viral-vector .
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com .
AUCATZYL® (obecabtagene autoleucel – obe-cel) is a registered trademark of Autolus Therapeutics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250731953715/en/
Source: AGC Biologics
Business Wire
-
08/19 13:00 Nikkiso Selected to Provide Regasification Systems and Engineering Ser...
-
08/19 04:09 Meitu Reports Strong First Half 2025 Financial Results as AI Applicati...
-
08/19 02:00 DIC CORPORATION: New Sustainable Production Facility for Coatings for...
-
08/19 02:00 Technologent Partners with ITOCHU Techno-Solutions Corporation to Laun...
-
08/18 23:10 SoftBank Group and Intel Corporation Sign $2B Investment Agreement
-
08/18 12:00 Eagle Point Credit Management Hires Ken Yamashita, Managing Director, ...
-
08/18 12:00 Maxell’s All-Solid-State Battery Modules Installed in Industrial Rob...
-
08/18 12:00 Lone Star Funds Completes Sale of 201-Unit Multifamily and Retail Prop...
-
08/18 05:00 Mitsubishi Electric’s Net Zero Energy Building Test Facility “SUST...
-
08/18 04:58 EXPO2025 Kochi Festival WORLD YOSAKOI DAY
-
08/18 01:00 EdgeCortix Completes Initial Close of Series B Financing, Driving Tota...
-
08/14 16:00 OKI Develops Tiling crystal film bonding (CFB) Technology for Heteroge...
-
08/14 14:00 GMO Internet Group’s White-Hat Team “GMO Ierae” Claims First Pla...
-
08/14 13:00 Xsolla Expands Payments in Asia to Support FPX, K PLUS, AIS, Indosat, ...
-
08/14 12:00 Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates...
-
08/14 08:33 MUFG Bank, Ltd. Announces Risk-Adjusted Capital Ratio Based on the Bas...
-
08/13 16:00 Nexon Releases Earnings for Second Quarter 2025
-
08/13 15:00 Celebrating the Osaka-Kansai Expo 2025 “Top Chef in OSAKA 2025” Fe...
-
08/13 13:15 INSERTING and REPLACING SBC Medical Group Holdings Announces Second Qu...
-
08/13 13:00 ENEOS Corporation Joins the Automotive Edge Computing Consortium
-
08/13 11:00 D-Wave Announces First-Ever Qubits Japan 2025 Quantum Computing User C...
-
08/12 16:30 Citcon and GMO Payment Gateway, Announce Strategic Partnership to Expa...
-
08/12 14:00 TDK Ventures Invests in Ultraviolette to Accelerate Electrification of...
-
08/12 14:00 Kuwana City, Mie: “English Friendly City” Logo Revealed!
-
08/12 10:59 Palantir and SOMPO Expand Partnership in Multi-Year Agreement
-
08/12 09:30 PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain...
-
08/12 00:00 Access Advance Video Distribution Patent Pool Gains Further Momentum w...
-
08/08 13:00 Yagi & Co., Ltd.: FUJILOOM™ Blankets, Mats, and Throw Towels Are...
-
08/08 03:20 FPT and ANA Systems Forge Strategic Partnership to Advance Digital Inn...
-
08/07 15:09 Motorola Solutions Completes Acquisition of Silvus Technologies Holdin...